FPRX - Five Prime Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Five Prime Therapeutics, Inc.

111 Oyster Point Boulevard
South San Francisco, CA 94080
United States
415-365-5600
http://www.fiveprime.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees209

Key Executives

NameTitlePayExercisedYear Born
Mr. Aron Marc KnickerbockerPres, CEO & Director731.07k24.2k1969
Mr. David V. SmithExec. VP & CFO454.98kN/A1960
Mr. Francis W. SarenaChief Strategy Officer & Sec.640.93kN/A1971
Dr. Helen Louise CollinsSr. VP & Chief Medical Officer610kN/A1963
Mr. David WhitePrincipal Accounting OfficerN/AN/A1964
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; a collaboration agreement with Roche; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Corporate Governance

Five Prime Therapeutics, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 6. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.